The extensive mutation rate of the KRAS oncogene has played detrimental roles in cancer initiation, propagation and maintenance and thus could be highlighted as a therapeutic target for specific treatment (Cox et al. 2014; Kim et al. 2018). This evidence concerns the gene KRAS and cancer.